Explore

Trendline Trendline
Mundipharma Reports Positive Results from Phase III Trial of Rezafungin for Fungal Disease Prevention

Mundipharma Reports Positive Results from Phase III Trial of Rezafungin for Fungal Disease Prevention

Mundipharma Reports Positive Results from Phase III Trial of Rezafungin for Fungal Disease Prevention
Trendline Trendline
Soligenix's Phase 3 Trial for HyBryte in CTCL Treatment Faces Setback

Soligenix's Phase 3 Trial for HyBryte in CTCL Treatment Faces Setback

Soligenix's Phase 3 Trial for HyBryte in CTCL Treatment Faces Setback
Trendline Trendline
AI Integration in Manufacturing: Enhancing Human Judgment Without Disrupting Operations

AI Integration in Manufacturing: Enhancing Human Judgment Without Disrupting Operations

AI Integration in Manufacturing: Enhancing Human Judgment Without Disrupting Operations
Trendline Trendline
AI Integration in Manufacturing: Enhancing Operations Without Disruption

AI Integration in Manufacturing: Enhancing Operations Without Disruption

AI Integration in Manufacturing: Enhancing Operations Without Disruption
Trendline Trendline
Mundipharma Reports Positive Results from Phase III Trial of Rezafungin for Fungal Disease Prophylaxis

Mundipharma Reports Positive Results from Phase III Trial of Rezafungin for Fungal Disease Prophylaxis

Mundipharma Reports Positive Results from Phase III Trial of Rezafungin for Fungal Disease Prophylaxis
Trendline Trendline
AI Start-up Profluent Partners with Eli Lilly for Gene-Editing Therapies

AI Start-up Profluent Partners with Eli Lilly for Gene-Editing Therapies

AI Start-up Profluent Partners with Eli Lilly for Gene-Editing Therapies
Rapid Read Rapid Read
Epigenetic Clocks and Biological Age Tests: Current Limitations and Implications

Epigenetic Clocks and Biological Age Tests: Current Limitations and Implications

Epigenetic clocks, which estimate biological age based on DNA, are gaining popularity as tools for understanding aging. These clocks measure chemical changes to DNA, known as epigenetic marks, to provide insights into how a person's body is aging. Despite their potential, these clocks are not yet reliable for individual health decisions. The variability in results, influenced by factors such as lifestyle and environmental exposures, makes them unsuitable for personal health guidance. Currently, there are no FDA-approved direct-to-consumer biological age tests, and the science behind these tests is still evolving.
Trendline Trendline
FDA Requests Amgen to Withdraw Tavneos Amid Data Manipulation Allegations

FDA Requests Amgen to Withdraw Tavneos Amid Data Manipulation Allegations

FDA Requests Amgen to Withdraw Tavneos Amid Data Manipulation Allegations
Rapid Read Rapid Read
FDA Partners with Amgen and AstraZeneca for Real-Time Clinical Trials Using Cloud Technology

FDA Partners with Amgen and AstraZeneca for Real-Time Clinical Trials Using Cloud Technology

The FDA has launched an initiative to streamline drug development and review processes through real-time clinical trials, utilizing cloud technology. Amgen and AstraZeneca are participating in this pilot program, which allows FDA reviewers to access safety signals and clinical endpoints in real-time during trials. AstraZeneca will apply this system in its Phase 2 TRAVERSE study for mantle cell lymphoma, while Amgen will use it for the Phase 1b STREAM-SCLC study in small cell lung cancer. The FDA has successfully validated data from AstraZeneca's program, demonstrating the feasibility of real-time data sharing. The agency is also seeking public feedback on the framework's design and implementation.
Trendline Trendline
Ambiq Introduces compressionKIT to Enhance Edge AI Efficiency in Wearable Devices

Ambiq Introduces compressionKIT to Enhance Edge AI Efficiency in Wearable Devices

Ambiq Introduces compressionKIT to Enhance Edge AI Efficiency in Wearable Devices
Trendline Trendline
Cellares and Cabaletta Bio Sign Long-Term Agreement for CAR T Cell Therapy Manufacturing

Cellares and Cabaletta Bio Sign Long-Term Agreement for CAR T Cell Therapy Manufacturing

Cellares and Cabaletta Bio Sign Long-Term Agreement for CAR T Cell Therapy Manufacturing
Rapid Read Rapid Read
Gene Therapy Leaders Push for Novel Regulatory Models to Aid Rare Disease Treatments

Gene Therapy Leaders Push for Novel Regulatory Models to Aid Rare Disease Treatments

Gene therapy leaders are advocating for new regulatory models to facilitate the development of personalized treatments for rare diseases. This push comes nearly a year after Baby KJ Muldoon received a groundbreaking CRISPR treatment for CPS1 deficiency, a rare genetic condition. The Innovative Genomics Institute, led by CRISPR pioneer Jennifer Doudna, is preparing to trial a similar treatment for another child with a different genetic disorder. The FDA's plausible mechanism pathway aims to accelerate gene therapies for small patient populations, but some in the biotech industry, like EveryONE Medicines, have found it insufficient for commercial viability. The pathway requires separate applications for each drug, which can be burdensome. Biopharma companies, including Aurora Therapeutics, are working to develop platform technologies to streamline the production of gene therapies for rare mutations.